Free Trial
→ Urgent: Invest In ‘Elon’s iPhone’ Before July 22nd (From StocksToTrade) (Ad)tc pixel Free CDNA Stock Alerts

CareDx (CDNA) Competitors

CareDx logo
$63.67 0.00 (0.00%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$64.06 +0.39 (+0.61%)
As of 05:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CDNA vs. SMMT, BBIO, HALO, MDGL, and BMRN

Should you buy CareDx stock or one of its competitors? CareDx's main competitors and comparable companies include Summit Therapeutics (SMMT), BridgeBio Pharma (BBIO), Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), and BioMarin Pharmaceutical (BMRN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CareDx compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and CareDx (NASDAQ:CDNA) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

CareDx has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Summit TherapeuticsN/AN/A-$1.08B-$1.12N/A
CareDx$458.09M7.19-$21.35M$2.0730.76

Summit Therapeutics has a beta of -1.51, suggesting that its stock price is 251% less volatile than the broader market. Comparatively, CareDx has a beta of 2.38, suggesting that its stock price is 138% more volatile than the broader market.

CareDx has a net margin of 24.23% compared to Summit Therapeutics' net margin of 0.00%. CareDx's return on equity of 2.87% beat Summit Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Summit TherapeuticsN/A -168.94% -141.92%
CareDx 24.23%2.87%2.17%

Summit Therapeutics currently has a consensus target price of $28.61, suggesting a potential upside of 62.64%. CareDx has a consensus target price of $54.00, suggesting a potential downside of 15.19%. Given Summit Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Summit Therapeutics is more favorable than CareDx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Summit Therapeutics
1 Sell rating(s)
8 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.53
CareDx
0 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.38

In the previous week, CareDx had 4 more articles in the media than Summit Therapeutics. MarketBeat recorded 6 mentions for CareDx and 2 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.18 beat CareDx's score of 0.68 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Summit Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
CareDx
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

4.6% of Summit Therapeutics shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by company insiders. Comparatively, 2.4% of CareDx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

CareDx beats Summit Therapeutics on 9 of the 16 factors compared between the two stocks.

How does CareDx compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and CareDx (NASDAQ:CDNA) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

BridgeBio Pharma presently has a consensus target price of $105.42, indicating a potential upside of 61.32%. CareDx has a consensus target price of $54.00, indicating a potential downside of 15.19%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe BridgeBio Pharma is more favorable than CareDx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BridgeBio Pharma
1 Sell rating(s)
2 Hold rating(s)
21 Buy rating(s)
0 Strong Buy rating(s)
2.83
CareDx
0 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.38

In the previous week, BridgeBio Pharma had 10 more articles in the media than CareDx. MarketBeat recorded 16 mentions for BridgeBio Pharma and 6 mentions for CareDx. CareDx's average media sentiment score of 0.68 beat BridgeBio Pharma's score of 0.57 indicating that CareDx is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BridgeBio Pharma
4 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
CareDx
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

BridgeBio Pharma has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, CareDx has a beta of 2.38, meaning that its share price is 138% more volatile than the broader market.

99.9% of BridgeBio Pharma shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 2.4% of CareDx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CareDx has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Pharma$502.08M25.44-$724.93M-$3.57N/A
CareDx$458.09M7.19-$21.35M$2.0730.76

CareDx has a net margin of 24.23% compared to BridgeBio Pharma's net margin of -97.03%. CareDx's return on equity of 2.87% beat BridgeBio Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
BridgeBio Pharma-97.03% N/A -61.19%
CareDx 24.23%2.87%2.17%

Summary

BridgeBio Pharma and CareDx tied by winning 8 of the 16 factors compared between the two stocks.

How does CareDx compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and CareDx (NASDAQ:CDNA) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Halozyme Therapeutics has a net margin of 24.86% compared to CareDx's net margin of 24.23%. Halozyme Therapeutics' return on equity of 260.98% beat CareDx's return on equity.

Company Net Margins Return on Equity Return on Assets
Halozyme Therapeutics24.86% 260.98% 23.91%
CareDx 24.23%2.87%2.17%

Halozyme Therapeutics currently has a consensus price target of $94.00, indicating a potential downside of 14.87%. CareDx has a consensus price target of $54.00, indicating a potential downside of 15.19%. Given Halozyme Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Halozyme Therapeutics is more favorable than CareDx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Halozyme Therapeutics
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.67
CareDx
0 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.38

In the previous week, Halozyme Therapeutics had 17 more articles in the media than CareDx. MarketBeat recorded 23 mentions for Halozyme Therapeutics and 6 mentions for CareDx. Halozyme Therapeutics' average media sentiment score of 0.73 beat CareDx's score of 0.68 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Halozyme Therapeutics
10 Very Positive mention(s)
6 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
CareDx
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Halozyme Therapeutics has higher revenue and earnings than CareDx. CareDx is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Halozyme Therapeutics$1.40B8.97$316.89M$3.3532.96
CareDx$458.09M7.19-$21.35M$2.0730.76

Halozyme Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, CareDx has a beta of 2.38, indicating that its share price is 138% more volatile than the broader market.

97.8% of Halozyme Therapeutics shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by company insiders. Comparatively, 2.4% of CareDx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Halozyme Therapeutics beats CareDx on 15 of the 16 factors compared between the two stocks.

How does CareDx compare to Madrigal Pharmaceuticals?

CareDx (NASDAQ:CDNA) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

CareDx has a net margin of 24.23% compared to Madrigal Pharmaceuticals' net margin of -25.32%. CareDx's return on equity of 2.87% beat Madrigal Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
CareDx24.23% 2.87% 2.17%
Madrigal Pharmaceuticals -25.32%-56.65%-25.53%

CareDx has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CareDx$458.09M7.19-$21.35M$2.0730.76
Madrigal Pharmaceuticals$1.28B8.49-$288.28M-$12.89N/A

CareDx has a beta of 2.38, indicating that its stock price is 138% more volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.04, indicating that its stock price is 204% less volatile than the broader market.

CareDx currently has a consensus price target of $54.00, indicating a potential downside of 15.19%. Madrigal Pharmaceuticals has a consensus price target of $710.20, indicating a potential upside of 50.55%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Madrigal Pharmaceuticals is more favorable than CareDx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CareDx
0 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.38
Madrigal Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
15 Buy rating(s)
0 Strong Buy rating(s)
2.78

In the previous week, Madrigal Pharmaceuticals had 1 more articles in the media than CareDx. MarketBeat recorded 7 mentions for Madrigal Pharmaceuticals and 6 mentions for CareDx. CareDx's average media sentiment score of 0.68 beat Madrigal Pharmaceuticals' score of 0.42 indicating that CareDx is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CareDx
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Madrigal Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 2.4% of CareDx shares are held by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

CareDx and Madrigal Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does CareDx compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and CareDx (NASDAQ:CDNA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

CareDx has a net margin of 24.23% compared to BioMarin Pharmaceutical's net margin of 2.14%. BioMarin Pharmaceutical's return on equity of 5.32% beat CareDx's return on equity.

Company Net Margins Return on Equity Return on Assets
BioMarin Pharmaceutical2.14% 5.32% 3.69%
CareDx 24.23%2.87%2.17%

BioMarin Pharmaceutical has higher revenue and earnings than CareDx. CareDx is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioMarin Pharmaceutical$3.22B3.29$348.90M$0.37148.08
CareDx$458.09M7.19-$21.35M$2.0730.76

BioMarin Pharmaceutical currently has a consensus price target of $87.82, indicating a potential upside of 60.28%. CareDx has a consensus price target of $54.00, indicating a potential downside of 15.19%. Given BioMarin Pharmaceutical's stronger consensus rating and higher probable upside, equities research analysts clearly believe BioMarin Pharmaceutical is more favorable than CareDx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioMarin Pharmaceutical
1 Sell rating(s)
7 Hold rating(s)
14 Buy rating(s)
1 Strong Buy rating(s)
2.65
CareDx
0 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.38

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 2.4% of CareDx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, BioMarin Pharmaceutical had 1 more articles in the media than CareDx. MarketBeat recorded 7 mentions for BioMarin Pharmaceutical and 6 mentions for CareDx. CareDx's average media sentiment score of 0.68 beat BioMarin Pharmaceutical's score of 0.28 indicating that CareDx is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioMarin Pharmaceutical
0 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
CareDx
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

BioMarin Pharmaceutical has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, CareDx has a beta of 2.38, suggesting that its stock price is 138% more volatile than the broader market.

Summary

BioMarin Pharmaceutical beats CareDx on 11 of the 17 factors compared between the two stocks.

Get CareDx News Delivered to You Automatically

Sign up to receive the latest news and ratings for CDNA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CDNA vs. The Competition

Export
MetricCareDxBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.29B$3.93B$7.25B$13.28B
Dividend YieldN/A3.65%2.52%22.58%
P/E Ratio30.7613.62275.5926.13
Price / Sales7.191,237.51595.0889.84
Price / CashN/A39.4627.3036.12
Price / Book10.8117.6310.976.16
Net Income-$21.35M-$22.69M$3.50B$381.12M
7 Day Performance-8.85%-1.63%-1.20%-1.46%
1 Month Performance26.68%-7.96%-4.00%-3.37%
1 Year Performance342.46%14.18%7.14%1.49%

CareDx Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CDNA
CareDx
2.3143 of 5 stars		$63.67
flat		$54.00
-15.2%		+342.5%$3.29B$458.09M30.76765
SMMT
Summit Therapeutics
2.5832 of 5 stars		$17.27
+3.1%		$28.61
+65.6%		-17.6%$13.37BN/AN/A265
BBIO
BridgeBio Pharma
3.9199 of 5 stars		$66.14
-1.7%		$102.61
+55.1%		+17.8%$13.15B$713.07MN/A839
HALO
Halozyme Therapeutics
3.2611 of 5 stars		$108.31
-1.4%		$91.20
-15.8%		+72.3%$12.47B$1.40B32.33423
MDGL
Madrigal Pharmaceuticals
3.1544 of 5 stars		$493.62
-1.2%		$710.20
+43.9%		+9.8%$11.54B$1.28BN/A915

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CDNA) was last updated on 10/12/2026 by MarketBeat.com Staff.
From Our Partners
Trump's about to unleash his Midterm Weapon
Trump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...
Monument Traders Alliance | Sponsoredtc pixel
Urgent Attention to Executive Order #14363 (Buy This Stock Before Oct. 20th
Marc Chaikin, a 60-year Wall Street veteran whose past clients include George Soros and Steve Cohen, built a s...
Chaikin Analytics | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Urgent: Invest In ‘Elon’s iPhone’ Before July 22nd
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
Five Seats Could Shift Washington’s Direction
Democrats need just five more seats to flip House control, with forecasts giving them a 61% to 85% chance ahea...
USA Capital Gold | Sponsoredtc pixel
I've seen this movie before (last time: 17,556%)
My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...
Crypto 101 Media | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Federal Reserve Reveals Disturbing New Plan To Control Your Money
Docket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...
Weiss Ratings | Sponsoredtc pixel